PDS Biotechnology Corp (PDSB)
Healthcare
Biotechnology
0.69 $
-1.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns PDS Biotechnology Corp (PDSB)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.5% of the shares are freely tradable; institutional investors hold 9.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
9.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
2.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
56Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 3.50 | 1,950,946 | +2.6 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.92 | 1,631,089 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.18 | 660,228 | +26.9 | 03/31/2026 |
| BlackRock Inc | 0.99 | 554,048 | +6.1 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.55 | 307,311 | +0.0 | 03/31/2026 |
| Blair William & Co | 0.54 | 300,000 | +20.0 | 03/31/2026 |
| Renaissance Technologies Corp | 0.40 | 220,800 | +25.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.78 | 995,421 | +0.0 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.05 | 586,163 | +0.0 | 04/30/2026 |
| Fidelity Extended Market Index | 0.72 | 403,907 | -0.4 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.